Literature DB >> 24408084

SYNTAX score and the risk of stent thrombosis after percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: an ACUITY trial substudy.

Mayank Yadav1, Philippe Généreux, Tullio Palmerini, Adriano Caixeta, Mahesh V Madhavan, Ke Xu, Sorin J Brener, Roxana Mehran, Gregg W Stone.   

Abstract

OBJECTIVE: We sought to investigate the relationship between the SYNTAX score (SS) and stent thrombosis (ST) in patients with non-ST-segment elevation acute coronary syndromes (NSTE-ACS) undergoing percutaneous coronary intervention (PCI).
BACKGROUND: The relationship between the SS and ST is undetermined.
METHODS: We stratified 2,627 patients undergoing PCI in the ACUITY trial by SS tertile according to the current population (true tertiles, SS <7, SS = 7-12, and SS >12) and by the SYNTAX trial (original SYNTAX tertiles, SS <23, SS = 23-32, and SS >32). Thirty-day and 1-year rates of definite/probable ST were determined for each tertile.
RESULTS: A total 30 (1.1%) and 41 (1.6%) definite/probable ST events occurred by 30 days and 1 year, respectively. When stratified by true tertiles, 30-day and 1-year rates of definite/probable ST were significantly greater in the highest tertile (SS >12; 2.0% and 2.8%) compared with the intermediate (SS = 7-12; 0.7% and 1.1%) and lowest tertiles (SS <7; 0.6% and 0.7%), P = 0.007 and P = 0.0009, respectively. When stratified by original SYNTAX tertiles, 30-day and 1-year rates of definite/probable ST were significantly greater in the highest (SS >32; 6.3% and 8.8%) and intermediate tertiles (SS = 23-32; 2.8% and 3.7%) compared with the lowest tertile (SS < 22; 0.8% and 1.2%), P <0.0001 for both. By multivariable analysis, the SS was an independent predictor for both 30-day and 1-year definite/probable ST.
CONCLUSIONS: In patients with NSTE-ACS undergoing PCI, the extent and severity of CAD, as assessed by the SS before revascularization, was strongly associated with the occurrence of ST both at 30 days and 1 year.
© 2014 Wiley Periodicals, Inc. © 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  ACS; NSTE-ACS; NSTEMI; SYNTAX score; stent thrombosis

Mesh:

Year:  2014        PMID: 24408084     DOI: 10.1002/ccd.25396

Source DB:  PubMed          Journal:  Catheter Cardiovasc Interv        ISSN: 1522-1946            Impact factor:   2.692


  6 in total

1.  Admission Value of Serum Cathepsin D Level Can be Useful for Predicting In-Hospital Mortality in Patients with NSTEMI.

Authors:  Harun Kundi; Ahmet Balun; Hulya Cicekcioglu; Mustafa Cetin; Emrullah Kiziltunc; Canan Topcuoglu; Muhammed Fevzi Kilinckaya; Ender Ornek
Journal:  Acta Cardiol Sin       Date:  2017-07       Impact factor: 2.672

Review 2.  Application of the SYNTAX score in interventional cardiology: A systematic review and meta-analysis.

Authors:  Pravesh Kumar Bundhun; Yashna Sookharee; Anita Bholee; Feng Huang
Journal:  Medicine (Baltimore)       Date:  2017-07       Impact factor: 1.889

Review 3.  Percutaneous Coronary Intervention, Coronary Artery Bypass Surgery and the SYNTAX score: A systematic review and meta-analysis.

Authors:  Pravesh Kumar Bundhun; Chandra Mouli Yanamala; Feng Huang
Journal:  Sci Rep       Date:  2017-03-02       Impact factor: 4.379

4.  A simple score for the prediction of stent thrombosis in patients with ST elevation myocardial infarction: TIMI risk index.

Authors:  Tufan Çınar; Yavuz Karabağ; Cengiz Burak; Veysel Ozan Tanık; Mahmut Yesin; Metin Çağdaş; İbrahim Rencüzoğulları
Journal:  J Cardiovasc Thorac Res       Date:  2019-08-07

5.  Value of GRACE and SYNTAX scores for predicting the prognosis of patients with non-ST elevation acute coronary syndrome.

Authors:  Xiao-Feng Wang; Ming Zhao; Fei Liu; Guo-Rong Sun
Journal:  World J Clin Cases       Date:  2021-11-26       Impact factor: 1.337

6.  Stent thrombosis in acute coronary syndromes: Patient-related factors and operator-related factors.

Authors:  Martin Kamenik; Petr Widimsky
Journal:  Anatol J Cardiol       Date:  2020-10       Impact factor: 1.596

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.